Genomes and Genes
biological response modifiers
Summary: Biological or synthetic agents that are capable of eliciting specific and/or non-specific effects on immune responsiveness, thereby ultimately leading to an improvement in overall health of the patient. These agents can be further subcategorized into those that facilitate a normal immune response, those that stimulate the immune response, those that are capable of inducing noncytotoxic immunosuppression, and those that increase the ability of the host to tolerate damage by the cytotoxic modalities of the treatment.
Publications225 found, 100 shown here
- Adverse reactions to biological modifiersRichard W Weber
Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
Curr Opin Allergy Clin Immunol 4:277-83. 2004..This review addresses adverse responses to these agents...
- Psoriatic arthritis treatment: biological response modifiersP J Mease
Seattle Rheumatology Associates, 1101 Madison St, 10th Floor, Seattle, WA 98104, USA
Ann Rheum Dis 64:ii78-82. 2005..Also, it will be useful to learn more about the effects of combining traditional disease modifying drugs and the newer biologicals...
- Laboratory monitoring of biologic therapiesJ J Cush
Rheumatology and Clinical Immunology, Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Dallas, TX 75231 4496, USA
Clin Exp Rheumatol 23:S90-2. 2005..Tuberculin skin testing using PPD is recommended before starting treatment with any TNF inhibitor...
- The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammationSalvatore Cuzzocrea
Institute of Pharmacology, School of Medicine, University of Messina, Messina, Italy
Mol Pharmacol 61:997-1007. 2002..Thus, 15d-PGJ(2) reduces the development of acute and chronic inflammation. Therefore, the cyclopentenone prostaglandin 15d-PGJ(2) may be useful in the therapy of acute and chronic inflammation...
- 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytesH Fahmi
Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Quebec, Canada
Osteoarthritis Cartilage 10:845-8. 2002..This study showed that the PPARgamma agonist, 15d-PGJ(2), exerts a dual effect on COX-2 production. The mechanisms by which 15d-PGJ(2) favors COX-2 production will be discussed...
- Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiersJerard Seghatchian
Blood Component Technology and Thrombosis Haemostasis Consultancy, 50 Primrose Hill Road, London NW3 3AA, UK
Transfus Apher Sci 34:125-30. 2006..between and within groups, in terms of various laboratory markers of biocompatibility and major biological response modifiers, indicating that much still remains to be done on various aspects of quality improvement to fully ..
- Structural development of biological response modifiers based on thalidomideYuichi Hashimoto
Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1 1 1 Yayoi, Bunkyo ku, Tokyo 113 0032, Japan
Bioorg Med Chem 10:461-79. 2002....
- Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsisWilliam L Macias
Lilly Research Laboratories, Indianapolis, Indiana, USA
Crit Care 9:R607-22. 2005..Such an interaction might warrant a change in the assumptions that underlie current trial designs...
- Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1Saranette Cheng
Osteoarthritis Research Unit, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Canada
J Biol Chem 279:22057-65. 2004..These data define mPGES-1 and Egr-1 as novel targets of PPARgamma and suggest that inhibition of mPGES-1 gene transcription may be one of the mechanisms by which PPARgamma regulates inflammatory responses...
- Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiersU K Buchwald
Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Curr Pharm Des 9:945-68. 2003..In this paper, we review the historical underpinnings and present and future applications of immune therapy for infectious diseases in light of current challenges to the field...
- Biological response modifiers in the management of rheumatoid arthritisStan G Louie
School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033, USA
Am J Health Syst Pharm 60:346-55. 2003The management of rheumatoid arthritis (RA) with biological response modifiers (BRMs) is reviewed...
- Polysaccharide biological response modifiersM Y K Leung
Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, N T, Hong Kong, People s Republic of China
Immunol Lett 105:101-14. 2006b>Biological response modifiers (BRMs) are substances which augment immune response...
- Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiersAlexander V Kabanov
College of Pharmacy, Department of Pharmaceutical Sciences, Nebraska Medical Center, Omaha 68198 6025, USA
Crit Rev Ther Drug Carrier Syst 19:1-72. 2002..Finally, Pluronic formulations were shown to enhance transgene expression in the body. This opens new possibilities for the use of Pluronic in gene therapies...
- Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonistsH H Lee
Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, D 10117 Berlin, Germany
Br J Dermatol 156:486-91. 2007..Patients with rheumatic diseases receiving antitumour necrosis factor (TNF)-alpha-based treatment may develop cutaneous reactions...
- Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective studyS Guignard
Rene Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B Department, Paris, France
Ann Rheum Dis 65:1631-4. 2006..To evaluate the efficacy of anti-tumour necrosis factor (TNF) treatments (given for rheumatological manifestations) in reducing uveitis flares in patients with spondylarthropathy in daily practice...
- Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?Bart G Denys
Department of Internal Medicine, AZ Sint Jan AV, Ruddershove 10, B 8000 Brugge, Belgium
Clin Sci (Lond) 112:281-9. 2007..Pending publication of the RCTs, the use of TNF-alpha blockade in sarcoidosis should remain in the realm of experimental treatment...
- Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritisRoy Fleischmann
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
Drugs Aging 24:239-54. 2007..Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNFalpha therapies, be determined by the practising physician and the patient...
- Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritisM C Hochberg
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201 USA
Ann Rheum Dis 62:ii13-6. 2003....
- Psoriatic arthritis: a guide for dermatology nursesAlice B Gottlieb
University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Dermatol Nurs 15:107-10, 113-8; quiz 119. 2003..It is imperative that dermatology nurses learn more about the basic immunology of psoriasis and PsA and the role of immunomodulation in their treatments...
- Therapeutic implications for interferon-alpha in arthritis: a pilot studyThomas Wong
Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
J Rheumatol 30:934-40. 2003..To evaluate the therapeutic potential of interferon-a (IFN-a) in osteoarthritis (OA) and rheumatoid arthritis (RA) by examining regulation of cytokine antagonist expression...
- The use of biological agents in the treatment of rheumatoid arthritisPeng Thim Fan
Ann Acad Med Singapore 36:128-34. 2007..In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed...
- TNF involvement and anti-TNF therapy of reactive and unclassified arthritisR Meador
Hospital of University of Pennsylvania, Philadelphia VA Medical Center, 19104, USA
Clin Exp Rheumatol 20:S130-4. 2002..The clinical effect on a potential underlying infection is not known, but several studies have suggested at least short-term effectiveness and safety of anti-TNF-alpha therapy in reactive and unclassified arthritis...
- TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritidesG Homeff
Department of Paediatrics, Martin Luther University Halle Wittenberg, Halle, Germany
Clin Exp Rheumatol 20:S137-42. 2002..However, without further studies no recommendations can be provided for indication for treatment, dosing, intervals and duration of treatment...
- Anti-TNF therapy for other inflammatory conditionsZ Tutuncu
The Center for Innovative Therapy, Division of Rheumatology Allergy and Immunology, UCSD, School of Medicine, La Jolla, California, USA
Clin Exp Rheumatol 20:S146-51. 2002..However, whether anti-TNFalpha therapy can be safely and efficaciously applied to these other inflammatory disorders requires further controlled studies...
- Side effects of anti-TNF therapy: current knowledgeC Antoni
Department of Medicine III, University Erlangen Nuernberg, Erlangen, Germany
Clin Exp Rheumatol 20:S152-7. 2002..Sufficient knowledge about these partly specific side effects is critical for rheumatologists who treat their patients with these very effective biologic drugs...
- Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanerceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
Cutis 71:25-9. 2003..The structure and mechanism of each drug will be reviewed, as well as the most recent clinical experience and safety data. The first article of this review will focus on the therapies that inhibit tumor necrosis factor alpha (TNF-alpha)...
- Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an updateA S M Giasuddin
Dept of Biochemistry, Medical College for Women and Hospital, Uttara, Dhaka
Bangladesh Med Res Counc Bull 31:88-94. 2005..g. TNFalpha, in RA as well as in other inflammatory autoimmune diseases in the near future...
- Biologic therapeutics in the treatment of psoriasis. Part 1: reviewRichard G Langley
Department of Medicine, Dalhousie University, Halifax, NS, Canada
J Cutan Med Surg 11:99-122. 2007....
- The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel diseaseZiad Reguiai
Department of Dermatology, Hopital Robert Debre, Reims, France
Am J Clin Dermatol 8:67-77. 2007..Additional comparative long-term studies are needed to determine the long-term efficacy and safety of anti-TNFalpha therapy and define its role in the management of PG, with or without accompanying IBD...
- Switching to etanercept in patients with rheumatoid arthritis with no response to infliximabE Di Poi
Division of Rheumatology, DPMSC, School of Medicine, University of Udine, Udine, Italy
Clin Exp Rheumatol 25:85-7. 2007..A moderate or good response was achieved with etanercept in 13 out of 18 patients. From our experience, etanercept can be considered as a good alternative choice when infliximab has failed...
- Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitorsWesley Mizutani
Talbert Medical Group, Fountain Valley, California, USA
Manag Care Interface 16:44-50, 55. 2003..Managed care organizations should encourage early diagnosis of rheumatoid arthritis, referral to a rheumatologist, and treatment with agents that reduce the overall costs of this debilitating disease...
- Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritisM Flendrie
UMC Nijmegen, The Netherlands
Ann Rheum Dis 62:ii30-3. 2003..Adverse events which occurred, leading to discontinuation, were similar to those from previous reports...
- Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritisSamuele M Marcora
School of Sport, Health, and Exercise Sciences, University of Wales, Bangor, United Kingdom
Am J Clin Nutr 84:1463-72. 2006..Tumor necrosis factor (TNF) is an important mediator of cachexia, and its blockade prevents catabolism in animal models. However, little evidence shows that anti-TNF therapy is effective in treating cachexia in humans...
- [The role of biological agents in the treatment of psoriatic arthritis, literature review]Éva Koó
Budai Irgalmasrendi Kórház, II Reumatológiai Osztály
Orv Hetil 147:1963-70. 2006..TNF-alpha inhibitors available in Hungary (infliximab, etanercept, adalimumab) are potential therapies for patients who have not adequately responded to traditional disease-modifying antirheumatic drugs...
- [Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation]C Rodriguez Moreno
Servicios de Farmacología Clínica, Complexo Hospitalario Universitario, Santiago de Compostela, A Coruna, Spain
An Med Interna 23:37-45. 2006..The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of these conditions...
- What have we learned in dermatology from the biologic therapies?Brian J Nickoloff
J Am Acad Dermatol 54:S143-51. 2006..Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area...
- Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patientsP Efthimiou
Division of Allergy, Immunology and Rheumatology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, USA
Ann Rheum Dis 65:1233-6. 2006..To understand the use of tumour necrosis factor (TNF)alpha inhibitors in refractory dermatomyositis and polymyositis in an academic centre...
- Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?C Y Lu
School of Medical Sciences, University of New South Wales, NSW, Australia
Intern Med J 36:19-27. 2006..Examination of utilization data is important for assessing the broader implications of arrangements for access to expensive pharmaceuticals under schemes such as the PBS...
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasP Geborek
Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
Ann Rheum Dis 64:699-703. 2005..To determine whether TNF blockers increase tumour risk in patients with RA...
- Treatment continuation in patients receiving biological agents or conventional DMARD therapyA Zink
German Rheumatism Research Centre, Berlin, Germany
Ann Rheum Dis 64:1274-9. 2005....
- Role of biological agents in immune-mediated inflammatory diseasesPetros Efthimiou
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA
South Med J 98:192-204. 2005..Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjögren syndrome...
- [Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases]J L Marenco de la Fuente
Seccion de Reumatologia, Hospital de Valme, Facultad de Medicina, Sevilla
Rev Clin Esp 205:127-36. 2005..Other potential biological drugs still in investigational phase are mentioned...
- Update on the mechanisms and efficacy of biological therapies for psoriasisJohn Koo
UCSF Psoriasis Treatment Center, Department of Dermatology, University of California, 515 Spruce Street, San Francisco, CA 94118, USA
J Dermatol Sci 38:75-87. 2005....
- Psoriatic arthritisPhilippe Goupille
EA 3853 Immuno Pharmaco Génétics of Therapeutic Antibodies IPGA, and Rheumatology Department, Trousseau Teaching Hospital, Francois Rabelais University, 37044 Tours cedex 9, France
Joint Bone Spine 72:466-70. 2005..TNF-alpha antagonists constitute a breakthrough in the management of psoriatic arthritis. Similar to rheumatoid arthritis and ankylosing spondylitis, psoriatic arthritis is entering a new era of evaluation and treatment...
- Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterK L Hyrich
Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, UK
Rheumatology (Oxford) 45:1558-65. 2006..These drugs are expensive and have the potential of serious toxicity. Therefore, it would be ideal to predict the patients who will respond, so that the use of these drugs can be targetted...
- Ankylosing spondylitis: new treatment modalitiesJan Brandt
Rheumatologische Praxisgemeinschaft, Berlin, Germany
Best Pract Res Clin Rheumatol 20:559-70. 2006..Ongoing research has proven these agents to be efficacious and safe in the short and medium term. Further, longer-term trials are awaited to address the issue of whether these therapies are true disease modifiers in AS...
- Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective studyAlfons A den Broeder
Department of Rheumatology and Orthopaedic Surgery, Sint Maartenskliniek, The Netherlands
J Rheumatol 34:689-95. 2007..To identify risk factors for surgical site infection (SSI) in patients with rheumatoid arthritis (RA) with special attention for anti-tumor necrosis factor (anti-TNF) treatment...
- The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitisOri Elkayam
Department of Rheumatology, Tel Aviv Sourasky Medical Center, Israel
Semin Arthritis Rheum 33:283-8. 2004..To assess the effect of anti-tumor necrosis factor (TNF) alpha therapies on the immunogenicity of pneumococcal vaccination in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS)...
- Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agentsR M Fleishmann
University of Texas, Southwestern Medical Center at Dallas Dallas, Texas, USA
Clin Exp Rheumatol 20:S35-41. 2002..Post approval, several safety concerns, including patients at risk for serious infection and the emergence of latent tuberculosis and other opportunistic infections have emerged with the use of anti TNF therapy...
- The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonistsJennifer Cole
Department of Pharmacy, Veterans Affairs North Texas Health Care System VANTHCS, Dallas, TX, USA
Rheumatol Int 27:369-73. 2007..940. Mortality rates were not significantly different: TNF-alpha 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality...
- Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic reviewR Ariza-Ariza
Rheumatology Service, Hospital Universitario Virgen Macarena, Seville, Spain
Rheumatology (Oxford) 46:529-32. 2007..To estimate the proportion of rheumatoid arthritis (RA) patients on anti-tumour necrosis factor (anti-TNF) who require dose escalation...
- New biologic therapies for psoriatic diseaseKimberly A Bohjanen
Department of Dermatology, University of Minnesota Medical School, USA
Minn Med 87:34-6. 2004....
- [The role of biologic agents in the therapy of ankylosing spondylitis]Pál Géher
Semmelweis Egyetem, Általános Orvostudományi Kar, Ill Belgyógyászati Klinika, Reumatológiai és Fizioterápiás Tanszéki Csoport, Budai Irgalmasrendi Kórház, I Reumatológiai Osztály, Budapest
Orv Hetil 147:1203-13. 2006..Though individual admission is feasible, biologic drugs are not under reimbursement in Hungary. High drug costs makes the implementation of this new therapeutic opportunity difficult in the daily medical practice...
- Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patientsC Salliot
Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
Rheumatology (Oxford) 46:327-34. 2007..To evaluate the rate of infections in rheumatic patients treated with tumour necrosis factor (TNF)-alpha blockers in daily practice and to determine potential risk factors of infections...
- Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics RegisterW G Dixon
British Society for Rheumatology Biologics Register Control Centre Consortium, Manchester, UK
Arthritis Rheum 54:2368-76. 2006....
- TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritisCristina Russo
Dipartimento di Medicina Interna e Specialistica, Ascoli Tomaselli Hospitals, University of Catania, Italy
Clin Sci (Lond) 109:135-42. 2005....
- Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha
Section of Infectious Diseases, Department of Medicine, Rush Medical College, Chicago, Illinois 60612 3833, USA
AIDS Res Hum Retroviruses 18:661-5. 2002..Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further...
- Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanerceptBoback Berookhim
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
Cutis 74:245-7. 2004..To our knowledge, this is the first report of its efficacy in the treatment of PV...
- Biological modifier therapy for the treatment of rheumatoid arthritisJohn K Jenkins
Department of Medicine, University of Mississippi Medical Center, Jackson 39216, USA
Am J Med Sci 323:197-205. 2002..The success of these agents underscores the investigative approaches to the pathogenesis of RA and the appropriate design of pharmaceutical agents to target specific proinflammatory molecules...
- [New drugs and treatment strategies for rheumatoid arthritis]Flavio Fantini
Cattedra di Reumatologia Università, Unità Operativa di Reumatologia, Azienda Ospedaliera Istituto Ortopedico Gaetano Pini, Milano
Recenti Prog Med 94:361-79. 2003....
- Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputumJuanita H Vernooy
Nutrition and Toxicology Research Institute Maastricht, Department of Pulmonology, Maastricht University, The Netherlands
Am J Respir Crit Care Med 166:1218-24. 2002....
- Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritisChristine R Culy
Adis International Limited, Auckland, New Zealand
Drugs 62:2493-537. 2002..Well controlled studies have also demonstrated the efficacy of etanercept in patients with psoriatic arthritis or polyarticular-course juvenile rheumatoid arthritis...
- Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathyS Schnarr
Hannover Medical School, Department of Internal Medicine, University of Hannover, Germany
Clin Exp Rheumatol 20:S126-9. 2002..This article summarises the preliminary results of 11 uSpA patients in 4 different trials treated with TNFalpha inhibitors...
- 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapyShufeng Zhou
Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University ofAuckland, New Zealand
Invest New Drugs 20:281-95. 2002..Similar to many biological response modifiers, DMXAA alone did not show striking anti-tumour activity in patients...
- [The pulmonological manifestations of rheumatoid arthritis]György Bernscherer
Bernscherer és Tsa Bt Budapest
Orv Hetil 149:1355-61. 2008..These are the biological response modifiers. Their main representatives are infliximab, adalimumab, and etanercept...
- The role of natural biopolymers in genotoxicity of mutagens/carcinogens eliminationEva Miadokova
Department of Genetics, Comenius University, Mlynska dolina, B L, Bratislava, Slovak Republic
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:493-6. 2005..cell wall of baker's yeast Saccharomyces cerevisiae is included into the class of biopolymers known as biological response modifiers (BRMs) with a broad range of activities, above all ones interfering with cancer therapy...
- Antiviral activity of biological response modifiers in a murine model of AIDS. Requirement for augmentation of natural killer cell activity and synergy with oral AZTP L Black
Southern Research Institute Frederick Research Center, MD, USA
Int J Immunopharmacol 18:633-50. 1996We employed the Rauscher murine leukemia virus (RMuLV) as a murine retrovirus model of AIDS, to test biological response modifiers (BRM) and antiviral agents for potential therapeutic activity against the human immunodeficiency virus (..
- Biologically active compounds from Aphyllophorales (polypore) fungiJordan K Zjawiony
Department of Pharmacognosy and National Center for Natural Product Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, Mississippi 38677 1848, USA
J Nat Prod 67:300-10. 2004..These high molecular weight compounds, often called biological response modifiers (BRM), or immunopotentiators, prevent carcinogenesis, show direct anticancer effects, and prevent ..
- Cereal non-cellulosic polysaccharides: structure and function relationship - an overviewG Muralikrishna
Department of Biochemistry and Nutrition, Central Food Technological Research Institute, Mysore, Karnataka, India
Crit Rev Food Sci Nutr 47:599-610. 2007..1 --> 3),(1 --> 4)-beta -glucans are known as biological response modifiers (BMS) as they are believed to modulate the immune response...
- Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladderA Morales
Department of Urology, Queen s University, Kingston, Canada
J Urol 166:1633-7; discussion 1637-8. 2001..This result has led to the search for other active and safer biological response modifiers. We investigated the efficacy of a mycobacterial cell wall extract (MCWE) from Mycobacterium phlei, ..
- Biological response modifiers for the treatment of superficial bladder tumorsA R Zlotta
Department of Urology, Erasme Hospital, University Clinics of Brussels, Belgium
Eur Urol 37:10-5. 2000For more than 20 years, superficial bladder tumors have been demonstrated to be sensitive to several biological response modifiers and especially to immunomodulators...
- Normal tissue complications after radiation therapyJolyon H Hendry
International Atomic Energy Agency, Division of Human Health, Applied Radiobiology and Radiotherapy Section, Vienna, Austria
Rev Panam Salud Publica 20:151-60. 2006..Potential modification to treatments include the use of biological response modifiers. The introduction of "response prediction" modifications to treatments might also be available in the ..
- Augmentation of anti-tumor immunity in low-responder mice by various biological response modifiers: analysis of effector mechanismT Toko
Department of Immunology, Kochi Medical School
Jpn J Cancer Res 80:1212-9. 1989In order to elucidate the role of biological response modifiers (BRMs) in anti-tumor immunotherapy, we examined their effect on the induction of anti-tumor immunity in low-responder mice which hardly exhibit anti-tumor resistance against ..
- Cancer Research Campaign review of radiobiology researchA Horwich
Royal Marsden Hospital, Sutton, Surrey, UK
Br J Cancer 67:198-201. 1993..of response using drug/radiation protocols, targeting techniques, growth factors and other biological response modifiers to support normal tissues, and modulation of DNA repair...
- Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategiesM Graf
Medical Department 3, Klinikum Grosshadern, University of Munich, Munich, Germany
Eur J Haematol 75:477-84. 2005..With respect to the individual PRR-status the benefit of biological response modifiers as priming agents, differentiation mediators or factors influencing cellular metabolisms inducing ..
- Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecanC J Langer
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 15:19-24. 2001..Planned combinations with new chemotherapeutic agents and biological response modifiers may provide additional treatment options.
- Imexon and biological response modifiers in murine models of AIDSM A Chirigos
United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, MD 21702
Int J Immunopharmacol 13:33-41. 1991..model of the human acquired immune deficiency syndrome for testing the ability of antiviral agents and biological response modifiers (BRM) to suppress viremia and retroviral disease...
- Cytokines and cognition--the case for a head-to-toe inflammatory paradigmCraig J Wilson
St Vincent Institute on Aging, St Vincent Hospitals and Health Services, Indianapolis, Indiana 46260, USA
J Am Geriatr Soc 50:2041-56. 2002..Peripheral administration of certain cytokines as biological response modifiers produces adverse cognitive effects in animals and humans...
- The rationale and future potential of angiogenesis inhibitors in neoplasiaG Gasparini
Division of Medical Oncology, Azienda Ospedali Riuniti Bianchi Melacrino Morelli, Reggio Calabria, Italy
Drugs 58:17-38. 1999..through modulation of neovascularisation, antiangiogenic agents need to be developed and evaluated as biological response modifiers. Therefore, adequate and well designed clinical trials should be performed for a proper evaluation of ..
- A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual diseaseD J Gottlieb
Department of Haematology, Royal Free Hospital, London, UK
Br J Cancer 60:610-5. 1989b>Biological response modifiers such as interleukin 2 (IL2) may be most effective in the setting of minimal residual disease...
- Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compoundsMichele Montrone
Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico IRCCS, National Cancer Institute, 33081, Aviano PN, Italy
Endocr Metab Immune Disord Drug Targets 9:113-31. 2009..These biological response modifiers exert their pleiotropic effects through the interaction with nuclear receptors, defined as retinoic ..
- Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxisA Bauhofer
Institute of Theoretical Surgery, University of Marburg, Baldingerstrasse, 35033 Marburg, Germany
Langenbecks Arch Surg 386:132-40. 2001New biological response modifiers are usually tested in reductionistic, pharmacological animal models by the determination of mechanistic endpoints (mortality rate, cellular/physiological parameters)...
- Performance and immune responses to dietary beta-glucan in broiler chicksC M Cox
Avian Immunobiology Laboratory, Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA, USA
Poult Sci 89:1924-33. 2010..Among immunomodulators, beta-glucans are known as biological response modifiers due to their ability to activate the immune system...
- Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoidsT Brodowicz
Clinical Division of Oncology, Department of Medicine I, University Hospital, Vienna, Australia
Br J Cancer 80:1350-8. 1999..Among many other biological response modifiers known to influence these mechanisms, the efficacy of retinoids and interferons in the treatment of ..
- The probiotic paradox: live and dead cells are biological response modifiersClifford A Adams
ANOZENE Nutritional Sciences, Antwerp, Belgium
Nutr Res Rev 23:37-46. 2010..However, the use of dead probiotics as biological response modifiers has several attractive advantages; such products would be very safe and have a long shelf-life.
- Beta-glucan-indomethacin combination produces no lethal effectsVaclav Vetvicka
University of Louisville, Department of Pathology, Louisville, KY, USA
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:111-6. 2009..They are typical biological response modifiers with pronounced immunomodulating activity. However, some questions about possible side effects remain.
- Protective effects of fungal (1-->3)-beta-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cellsDarina Slamenova
Cancer Research Institute, Slovak Academy of Sciences, 833 91 Bratislava, Slovakia
Cancer Lett 198:153-60. 2003beta-Glucans belong to the class of substances known as biological response modifiers with a broad range of activity...
- Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignanciesLuca Laurenti
Istituto di Semeiotica Medica, Divisione di Ematologia, Policlinico A Gemelli, Largo A Gemelli, 8 00168 Rome, Italy
Haematologica 87:59-66. 2002....
- Yeast-derived beta-glucan in combination with anti-tumor monoclonal antibody therapy in cancerJingjing Liu
Tumor Immunobiology Program, James Graham Brown Cancer Center, Department of Microbiology and Immunology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
Recent Pat Anticancer Drug Discov 4:101-9. 2009..beta-Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy...
- Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stressL Lippiello
Nutramax Laboratories Inc, 2208 Lakeside Boulevard, Edgewood, MD 21040, USA
Osteoarthritis Cartilage 11:335-42. 2003..To test the hypothesis that chondrocytes are more responsive to the chondroprotective agents, glucosamine (glcN) and chondroitin sulfate (CS), under in vitro conditions simulating in vivo joint stress...
- Structure and function of sinusoidal lining cells in the liverE Wisse
Laboratory for Cell Biology and Histology, Brussels Jette, Belgium
Toxicol Pathol 24:100-11. 1996..The number and cytotoxicity of pit cells can be considerably enhanced with biological response modifiers, such as Zymosan or interleukin 2 (8)...
- Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing miceJarek Baran
Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, KY, USA
Folia Histochem Cytobiol 45:107-14. 2007Beta (1-3)-D-glucans were identified almost 40 years ago as biological response modifiers that stimulated tumor rejection...
- Differential expression of a stress-modulating gene, BRE, in the adrenal gland, in adrenal neoplasia, and in abnormal adrenal tissuesJ Miao
Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China
J Histochem Cytochem 49:491-500. 2001..Many of these biological response modifiers are responsible for various pathological conditions, including inflammation, infection, cachexia, ..
- Protection against murine cytomegalovirus infection in aged mice and mice with severe combined immunodeficiency disease with the biological response modifiers polyribosinic-polycytidylic acid stabilized with L-lysine and carboxymethylcellulose, maleic anhS C Kunder
Department of Microbiology and Immunology, Medical College of Pennsylvania, Philadelphia 19129
Antiviral Res 21:233-45. 1993A variety of biological response modifiers (BRMs) have provided antiviral protection to immunocompetent mice, and this prompted us to determine their efficacy against murine cytomegalovirus (MCMV) infection in immunocompromised mice-..
- Idiopathic hirsutismR Azziz
Department of Obstetrics and Gynecology, The University of Alabama at Birmingham, 35233 7333, USA
Endocr Rev 21:347-62. 2000..New therapeutic strategies such as laser epilation or the use of new biological response modifiers may play an important role in offering a more effective means of treatment to remove unwanted hair...
- Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancerJun Yan
James Graham Brown Cancer Center, Tumour Immunobiology Program, University of Louisville, 580 S Preston Street, Louisville, KY 40202, USA
Expert Opin Biol Ther 5:691-702. 2005Beta-glucans, biological response modifiers (BRMs) derived from the cell walls of yeast and other sources, have been demonstrated to prime leukocyte complement receptor 3 (CR3), thus enabling these cells to kill tumours opsonised with ..
- Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysisKristian Reich
Dermatologikum Hamburg, Hamburg, Germany
Curr Med Res Opin 24:1237-54. 2008The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated.
- Structural development of biological response modifiers based on retinoids and thalidomideYuichi Hashimoto
Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1 1 1 Yayoi, Bunkyo ku, Tokyo, 113 0032, Japan
Mini Rev Med Chem 2:543-51. 2002..In this situation, biological response modifiers (BRM's), which are not based on selective toxicity, are expected to be useful...
- [Brain metastases of malignant melanomas]C Boaziz
Service d Oncologie Medicale, Hopital Avicenne, Bobigny, France
Bull Cancer 78:347-53. 1991..Neither do the biological response modifiers like Interleukin 2 (Il2) that leads to 25% response rate in disseminated melanoma...
- A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanomaE Bajetta
Unit of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Tumori 87:219-22. 2001....
- The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha miceH F Havas
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140
J Biol Response Mod 9:194-204. 1990..MBV compares favorably with other biological response modifiers because of its enhancing effect on the immune response and its oncolytic properties at nontoxic levels.
- Deep South Musculoskeletal (DSM) CERTsKenneth G Saag; Fiscal Year: 2010..Since 1998, over 15 new treatments have been FDA approved for MSDs, including novel biological response modifiers. Despite significant efficacy in clinical trials, questions and concerns persist about the safety, ..
- Modulating Innate and Adaptive Immunity in Complicated Abdominal SepsisFrederick A Moore; Fiscal Year: 2012..b>Biological response modifiers (BRMs) have targeted individual components of the inflammatory response, microbial recognition, ..
- Prevalence and immunogenicity of HNA-3a and -3b antibodies and antigensRICHARD HERBERT ASTER; Fiscal Year: 2012..fatality, is triggered by transfusion of blood products containing leukocyte antibodies and/or biological response modifiers to susceptible patients...
- ENHANCEMENT OF PDT USING BIOLOGICAL RESPONSE MODIFIERSDavid A Bellnier; Fiscal Year: 2010....
- Validation of a Genomics Based Prognostic in Severe TraumaLyle L Moldawer; Fiscal Year: 2013..understanding of the basic pathophysiology of severe trauma and its sequelae, there are essentially no biological response modifiers that have proven successful in prospective, randomized clinical trials...
- Collection, Storage, Advertisements, & Distribut of Biological Response ModifiersHANNAH ELSON; Fiscal Year: 2010..Between April 1996 and August 2008 the repository contractor distributed, on behalf of the NCI, over 43,000 vials of reagents to hundreds of institutions. ..
- Collection, Storage, Advertisements, &Distribut of Biological Response ModifiersHANNAH ELSON; Fiscal Year: 2009..Between April 1996 and August 2008 the repository contractor distributed, on behalf of the NCI, over 43,000 vials of reagents to hundreds of institutions. ..
- Keratinocyte Costimulation and Th2-Cell Immune DeviationAnthony Gaspari; Fiscal Year: 2009..Similar mechanistic studies of the molecular basis of other skin diseases such as psoriasis have led to the development of biological response modifiers that are now in clinical use.
- Planning a Multi-Center Trial of Interferon-gamma in Trauma PatientsRONALD GARY TOMPKINS; Fiscal Year: 2012..A primary objective is to determine whether rhIFN-? reduces "time to recovery" and increases "organ-failure free days" in the subgroup of patients identified by the prognostic test to be at increased risk. ..
- PEDIATRIC ONCOLOGY GROUPStephen Lauer; Fiscal Year: 2002..in tumor-suppressor genes); in vitro sensitivity of leukemia cells to antineoplastic agents mid biological response modifiers; mechanisms of resistance of AML cells to alkylating agents; molecular neuro-oncology; and xenogeneic ..
- PERIODONTAL LIGAMENT CELL AUTOCRINE FACTORVICTOR TERRANOVA; Fiscal Year: 1993..b>Biological response modifiers to be co-examined along with the PDL-CTX and PDL-CTX-R (PDL-CTX-receptor) include FGF, PDGF, TGF-beta ..
- Antiviral Compounds for Human Papillomavirus 16Christopher Fisher; Fiscal Year: 2005..Current treatments, which include surgery, freezing, noxious agents, and =biological response modifiers," are primitive or non-specific...
- OXIDANT STRESS AND ENDOTHELIAL CELL METABOLISMLORRAINE SORDILLO; Fiscal Year: 2001..Se-deficient endothelial cells, 2) to evaluate the effects of Se deficiency on the production of such biological response modifiers as cytokines, PAF and NO in relation to altered eicosanoid production and 3) to evaluate the effects ..
- BINDING OF ALLERGENS TO LIPOSOMES FOR IMMUNOTHERAPYARISTO WOJDANI; Fiscal Year: 1990..used by other investigators, in this study our major goal is to encapsulate standardized allergens and biological response modifiers (BRMs) to different liposomes and study the effect of this modification on their allergenicity and ..
- Biowarfare applications of a new immunoregulatorKENNETH WILLEFORD; Fiscal Year: 2003..Scientists at GeneBact Biotechnologies, Inc. have discovered a new class of Biological Response Modifiers from mammalian serum that we refer to as the Immune Cell Proliferation Factors ("ICPF")...
- PRIMARY BREAST CANCER THERAPY GROUP-NSABPDaniel Karp; Fiscal Year: 1991..oncogenes, 3) estrogen receptor assay research development and 4) clinical application of the role of biological response modifiers such as IL-2 and lymphokine activated cytotoxity and tuftsin and mechanisms of estrogen/tamoxofin on ..
- NOVEL MARROW PURGING REGIMENS IN LEUKEMIAJoseph Wiley; Fiscal Year: 1992..will develop principles for the application of combination purging with chemotherapeutic agents and biological response modifiers in clinical treatment of leukemic marrow and form the basis for the applicant's career development as ..
- PEDIATRIC ONCOLOGY GROUP--PHASE I TRIALS IN CHILDRENSharon Murphy; Fiscal Year: 2000..are to: (1) establish the maximum tolerated dose and dose-limiting toxicities of new cytotoxic agents, biological response modifiers, or maturational agents; (2) determine the quantitative and qualitative toxicity of new agents, the ..
- REGULATION OF PRODUCTION OF GAMMA INTERFERON IN TUMORHoward Johnson; Fiscal Year: 1990..of the brain where AVP and its receptor are present as well as cells capable of producing classic biological response modifiers. The objective of this proposal is to determine the mechanism by which AVP positively regulates ..
- PHASE I/II TRIAL, INTRACAVITARY LAK/IL-2 IN BRAIN TUMORSMaxim Koslow; Fiscal Year: 1991..Alternative approaches to cancer therapy have focused on the use of biological response modifiers (BRMs) as antitumor agents...
- CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERSMICHAEL LOTZE; Fiscal Year: 1999..4) More approaches utilizing T-cell defined tumor epitopes in constructing tumor vaccine. ..
- TUMOR GROWTH INHIBITION BY INTERFERON B AND RETINOIDSDHAN KALVAKOLANU; Fiscal Year: 2001Interferons (IFNs) and retinoids are powerful biological response modifiers. Although they are effective growth inhibitors of certain transformed cells, both these agents have limited efficacy as single agents against many tumors...
- TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODYTSANN CHU; Fiscal Year: 1990..Effectiveness of both therapies will be potentiated by biological response modifiers. The proposed approaches to the use of a unique monoclonal antibody in targeting and therapy of ..
- ANTINEOPLASTIC ALKYLGLYCEROLIPIDSCLAUDE PIANTADOSI; Fiscal Year: 1990..ALPs may be directly cytotoxic to tumor cells or may function as biological response modifiers, or may exhibit both effects...
- BIOLOGICAL RESPONSE MODIFIERS IN TRANSFUSION MEDICINEEdward Snyder; Fiscal Year: 1993..Adapted from applicant's abstract)Support is requested for a scientific meeting entitled "The Role of Biological Response Modifiers in Molecular and Clinical Transfusion Medicine", to be held Thursday- Friday, September 9-10, 1993 in ..
- HSV VECTORS FOR THE DESTRUCTION OF BRAIN TUMORSNigel Fraser; Fiscal Year: 2005..the effectiveness of HSV-1 based tumor destruction by engineering HSV-1 mutants that will express biological response modifiers, such as an angiogenesis inhibitor specifically within tumors cells...
- EASTERN COOPERATIVE ONCOLOGY GROUPBarbara Grant; Fiscal Year: 1992..New initiatives in treatment with biological response modifiers such as interleukin-2 and LAK cells and a planned program of autologous bone marrow transplantation ..
- PRODUCTION OF NATURAL KILLER CELLSSYLVIA POLLACK; Fiscal Year: 1992..be used to assess the effects on NK lineage cells of the neutrophilia-inducing tumor CE1460 and the biological response modifiers AIPP (2-amino-5-iodo-6-phenyl-4-pyrimidinone) and OK-432 (a pharmaceutical preparation of ..
- TUMOR NECROSIS FACTOR INDUCES A NEW REGULATORY CYTOKINEPRAVIN SEHGAL; Fiscal Year: 1991..These studies are likely to provide insights important to the use of biological response modifiers such as TNF and IFN-Beta2 in the clinic against neoplastic diseases.
- FIBROBLAST ACTIVATIONArnold Postlethwaite; Fiscal Year: 1993..The macrophage produces two classes of biological response modifiers, [interleukin 1 (IL-1) and transforming growth factor Beta (TGF) Beta] that are capable of modulating ..
- Finding membrane proteins in cutaneous T-cell lymphomasPRISKA VON HALLER; Fiscal Year: 2003..Despite the impact of biological response modifiers, such as interferon alpha, there still remains up to 25 to 50% of patients who present with advanced ..
- INTERNATIONAL CONFERENCE ON RENAL CARCINOMAJean de Kernion; Fiscal Year: 1992..The second session will consider tumor suppressor genes, oncogenes and growth factor. The third session is on determinants of biological behavior: invasion and metastases. The fourth session will cover biological response modifiers.
- Neurobiology of MIF in development and diseaseBradley Pearce; Fiscal Year: 2007..2, and its amino acid sequence has minimal homology with other identified biological response modifiers in mammals...
- BIOLOGICAL MODIFIERSRobert Sidwell; Fiscal Year: 1993Partial support is sought for the 2nd International Congress on Biological Response Modifiers (BRM), which is being organized by the Inter-American Society for Chemotherapy, Inc. (IASC)...
- CLINICAL RESEARCH IN NEURO-ONCOLOGYROY PATCHELL; Fiscal Year: 2004..uses of the device, including use with non-conventional agents such as anti-angiogenesis factors, biological response modifiers, radiation cell sensitizers, and other compounds. Dr...
- Cancer Immunotherapy w/In-Situ Maturated Dendritic cellsEli Gilboa; Fiscal Year: 2006..the optimal conditions for in situ maturation using classical adjuvants and whether local injection of biological response modifiers (BRMs) in the form of mRNA can contribute to the generation of potent immunostimulatory DC...
- CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS-TASK AAlbert LoBuglio; Fiscal Year: 1999..We will be further evaluating other new targeting agents for inclusion into future phase I and phase II clinical trials. ..
- MALIGNANT CELL GROWTH MODULATION BY INTERLEUKIN-1EDWIN GAFFNEY; Fiscal Year: 1990..of this dual- role is unclear, but bifunctional regulatory activities have been observed for other biological response modifiers. This proposal outlines three approaches to elucidate the mechanisms underlying the growth modulating ..
- BIOLOGICAL RESPONSE MODIFIERSJOAN RENER; Fiscal Year: 1990..In some instances production and initial purification of biologics, such as monoclonal antibodies for clinical trails is performed...
- ANIMAL MODELS OF HUMAN VIRAL INFECTIONSRobert Sidwell; Fiscal Year: 2000..mice which have been used successfully for evaluating influenza virus-inhibitory compounds and biological response modifiers (BRMs) in the now-terminating NIAID Animal Models contract...
- Rapid Screen for Genotoxicants, Chemoprotectors, and RadioprotectorsStephen Dertinger; Fiscal Year: 2006..This project addresses a stated need of investigators working to develop the next generation of biological response modifiers (BRMs)...
- SHARED TUMOR IDIOTOPES OF B CELL NEOPLASMSRichard Miller; Fiscal Year: 1991..anti-Id MoAbs conjugated to cytotoxic radioisotopes or administered in conjunction with other biological response modifiers. Overall, the results of the Phase 1 and 2 studies should lead to the practical development of anti-Id ..
- PHASE I/II CLINICAL STUDIES OF BIOLOGICAL RESPONSEJANICE GABRILOV; Fiscal Year: 1993..protocol for each trial will be developed by the contractor in collaboration with staff of the Biological Response Modifiers Program, NCI, and protocols must have NCI and FDA approval before they can be activated...
- INTERNATIONAL CONFERENCE ON IMMUNOMODULATING DRUGSHideyo Yamaguchi; Fiscal Year: 1992..applications of immunomodulating drugs either alone or in combination therapies, peptides as immunomodulating agents, immunotherapy of infectious diseases, and the role of various biological response modifiers in clinical therapies.
- CUTANEOUS ONCOLOGYMadeleine Duvic; Fiscal Year: 2004..Young physicians and students who receive advanced training in the proper detection, prevention, and treatment of skin cancers will be a resource and may improve outcomes for patients of the future. ..
- TRAINING GRANT IN MOLECULAR CARDIOLOGYMark Entman; Fiscal Year: 2008..This integrated design has consistently proven to be effective in providing successful independent and competitive investigators in molecular biology of cardiovascular medicine. ..
- Pathogenesis and Treatment of Alcohol-Induced CirrhosisBruce Cronstein; Fiscal Year: 2007..Specific Aim: Investigate the intracellular mechanisms involved in signaling an increase in collagen production (cAMP pathway, MAPK pathway, CREB phosphorylation). ..